At 12 months, the rates of the primary end point for efficacy were 55% in the percu-taneous-repair group and 73% in the surgery group (P = 0.007). The respective rates
of the components of the primary end point were as follows: death, 6% in each group;
surgery for mitral-valve dysfunction, 20% versus 2%; and grade 3+ or 4+ mitral
regurgitation, 21% versus 20%. Major adverse events occurred in 15% of patients in
the percutaneous-repair group and 48% of patients in the surgery group at 30 days
(P